10,767 Shares in Pfizer Inc. $PFE Acquired by Blankinship & Foster LLC

Blankinship & Foster LLC bought a new position in Pfizer Inc. (NYSE:PFE) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 10,767 shares of the biopharmaceutical company’s stock, valued at approximately $261,000.

Several other large investors have also recently made changes to their positions in PFE. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer during the 1st quarter valued at $27,000. Curio Wealth LLC lifted its stake in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the last quarter. Bayforest Capital Ltd purchased a new stake in Pfizer during the first quarter valued at about $28,000. Harbor Asset Planning Inc. purchased a new position in shares of Pfizer in the second quarter worth about $29,000. Finally, WPG Advisers LLC bought a new stake in shares of Pfizer in the 1st quarter valued at about $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. UBS Group reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Scotiabank initiated coverage on shares of Pfizer in a report on Thursday. They set a “sector outperform” rating and a $30.00 price target for the company. Finally, Bank of America increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $28.28.

Pfizer Stock Performance

Shares of PFE stock opened at $25.08 on Friday. The firm has a market capitalization of $142.57 billion, a price-to-earnings ratio of 13.34, a PEG ratio of 0.81 and a beta of 0.54. The stock has a fifty day moving average of $24.80 and a 200 day moving average of $24.45. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is presently 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.